Inflammation and aging: signaling pathways and intervention therapies

X Li, C Li, W Zhang, Y Wang, P Qian… - Signal Transduction and …, 2023 - nature.com
Aging is characterized by systemic chronic inflammation, which is accompanied by cellular
senescence, immunosenescence, organ dysfunction, and age-related diseases. Given the …

mTOR: Role in cancer, metastasis and drug resistance

AK Murugan - Seminars in cancer biology, 2019 - Elsevier
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that gets inputs from
the amino acids, nutrients, growth factor, and environmental cues to regulate varieties of …

[HTML][HTML] Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations

H Northrup, ME Aronow, EM Bebin, J Bissler… - Pediatric Neurology, 2021 - Elsevier
Background Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disease
affecting multiple body systems with wide variability in presentation. In 2013, Pediatric …

Targeting the PI3K pathway in cancer: are we making headway?

F Janku, TA Yap, F Meric-Bernstam - Nature reviews Clinical oncology, 2018 - nature.com
Abstract The PI3K–AKT–mTOR pathway is one of the most frequently dysregulated
pathways in cancer and, consequently, more than 40 compounds that target key …

The PI3K pathway in human disease

DA Fruman, H Chiu, BD Hopkins, S Bagrodia… - Cell, 2017 - cell.com
Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth
factor receptors, and elevated PI3K signaling is considered a hallmark of cancer. Many PI3K …

NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines

RJ Motzer, E Jonasch, S Boyle, MI Carlo… - Journal of the National …, 2020 - jnccn.org
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for
diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC) …

Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management

C McCarthy, N Gupta, SR Johnson, JY Jane… - The Lancet …, 2021 - thelancet.com
Lymphangioleiomyomatosis (LAM) is a slowly progressive, low-grade, metastasising
neoplasm of women, characterised by infiltration of the lung parenchyma with abnormal …

Research progress of mTOR inhibitors

Y Chen, X Zhou - European journal of medicinal chemistry, 2020 - Elsevier
Mammalian target of rapamycin (mTOR) is a highly conserved Serine/Threonine (Ser/Thr)
protein kinase, which belongs to phosphatidylinositol-3-kinase-related kinase (PIKK) protein …

[HTML][HTML] Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind …

JA French, JA Lawson, Z Yapici, H Ikeda, T Polster… - The Lancet, 2016 - thelancet.com
Background Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used
for various benign tumours associated with tuberous sclerosis complex. We assessed the …

Tuberous sclerosis complex

EP Henske, S Jóźwiak, JC Kingswood… - Nature reviews Disease …, 2016 - nature.com
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that affects multiple
organ systems and is caused by loss-of-function mutations in one of two genes: TSC1 or …